Use este identificador para citar ou linkar para este item:
https://repositorio.pucgoias.edu.br/jspui/handle/123456789/3011
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.creator | Lino, Gabriela Maia Almeida Brandão | - |
dc.creator | Pires, Milena Coutinho | - |
dc.date.accessioned | 2021-12-16T02:57:30Z | - |
dc.date.available | 2021-12-16T02:57:30Z | - |
dc.date.issued | 2019-10-18 | - |
dc.identifier.uri | https://repositorio.pucgoias.edu.br/jspui/handle/123456789/3011 | - |
dc.description.abstract | Psoriasis is a chronic systemic inflammatory disease with a major impact on patients' quality of life. The most common presentation is plaque psoriasis or psoriasis vulgaris. Mild illnesses are treated initially with topical medications, while moderate/severe conditions may have topical therapy associated with phototherapy and possibly combined with systemic therapy or the option of using immunobiological agents. The use of immunobiologicals has been shown to be a good option for the treatment of moderate/severe psoriasis, presenting better results in reducing the symptoms and improving the quality of life of the patient. Among the immunobiological drugs inhibiting IL-17 are secukinumab, ixekizumab and brodalumab. Objectives: To verify the efficacy of the use of IL-17 inhibitors (secukinumab, brodalumab and ixekizumab) in the treatment of moderate to severe psoriasis. Conclusion: Ixekizumab was considered the most effective immunobiological in the short-term treatment for moderate to severe plaque psoriasis in terms of PASI 75 and PASI 90, followed by Secukinumab and Brodalumab. Although the short-term effects of biological agents on moderate to severe psoriasis are well documented, studies examining long-term efficacy and safety are more limited and need better evaluation. | pt_BR |
dc.description.sponsorship | Não recebi financiamento | pt_BR |
dc.language | por | pt_BR |
dc.publisher | Pontifícia Universidade Católica de Goiás | pt_BR |
dc.relation | Recursos dos próprios autores. | pt_BR |
dc.rights | Acesso Aberto | pt_BR |
dc.subject | Psoríase | pt_BR |
dc.subject | Terapia biológica | pt_BR |
dc.subject | Interleucina-17 | pt_BR |
dc.subject | Secukinumab | pt_BR |
dc.subject | Ixekizumabe | pt_BR |
dc.subject | Brodalumabe | pt_BR |
dc.title | Terapia imunológica com inibidor da interleucina-17 no tratamento de psoríase vulgar | pt_BR |
dc.title.alternative | Immunological therapy with interleucin-17 inhibitor in treatment of vulgar psoriasis | pt_BR |
dc.type | Trabalho de Conclusão de Curso | pt_BR |
dc.contributor.advisor1 | Rocha Sobrinho, Hermínio Maurício da | - |
dc.contributor.advisor1ID | https://orcid.org/0000-0002-7521-3700 | pt_BR |
dc.contributor.advisor1Lattes | http://lattes.cnpq.br/5573574130526137 | pt_BR |
dc.contributor.referee1 | Costa, Natália Moriya Xavier da | - |
dc.contributor.referee1Lattes | http://lattes.cnpq.br/1519406580343535 | pt_BR |
dc.contributor.referee2 | Aveiro, Nayana Chaves | - |
dc.contributor.referee2Lattes | http://lattes.cnpq.br/5245608418892000 | pt_BR |
dc.description.resumo | A psoríase é uma doença inflamatória crônica sistêmica de grande impacto na qualidade de vida dos doentes. Tem como apresentação mais frequente a psoríase em placas ou psoríase vulgar. Quadros leves da doença são tratados inicialmente com medicações tópicas, enquanto quadros moderados/graves podem ter a terapia tópica associada a fototerapia e, eventualmente, combinada a terapia sistêmica, ou ainda opção do uso de imunobiológicos. O uso de imunobiológicos tem se mostrado uma boa opção para o tratamento da psoríase moderada/grave, apresentando melhores resultados na redução dos sintomas e melhora da qualidade de vida do paciente. Entre os medicamentos imunobiológicos inibidores da IL-17 destacam-se o secuquinumabe, ixekizumabe e brodalumabe. Objetivos: Abordar a eficácia do uso de imunobiológicos inibidores da IL-17 (secukinumab, brodalumabe e ixekizumab) no tratamento da Psoríase moderada a grave. Conclusão: O Ixekizumab foi considerado o imunobiológico mais eficaz no tratamento a curto prazo para psoríase em placas moderada a grave em termos de PASI 75 e PASI 90, seguido por Secukinumab e Brodalumab. Embora os efeitos a curto prazo dos agentes biológicos na psoríase moderada a grave estejam bem documentados, estudos que examinam a eficácia e a segurança a longo prazo são mais limitados e carecem de melhores avaliações. | pt_BR |
dc.publisher.country | Brasil | pt_BR |
dc.publisher.department | Escola de Ciências Médicas, Farmacêuticas e Biomédicas | pt_BR |
dc.publisher.initials | PUC Goiás | pt_BR |
dc.subject.cnpq | CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::ALERGOLOGIA E IMUNOLOGIA CLINICA | pt_BR |
dc.relation.references | BAGEL, J. et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. Journal of the American Academy of Dermatology, v. 77, n. 4, p. 667-674, 2017. BISSONNETTE, R. et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). Journal of the European Academy Dermatology and Venereology; v. 32, n. 9, p. 1507-1514, 2018. BLAUVELT, A. et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology, v. 77, n. 5, p. 855-862, 2017. CONITEC, Comissão Nacional de Incorporação de Tecnologias no SUS. ADALIMUMABE, ETANERCEPTE, INFLIXIMABE, SECUQUINUMABE E USTEQUINUMABE PARA PSORÍASE MODERADA A GRAVE. Relatório para sociedade. Disponível em: <www.conitec.gov.br >. Acesso em 17 jul. 2018. CHIRICOZZI, A; KRUEGER, J. IL-17 targeted therapies for psoriasis. Expert Opin. Invest. Drugs, v. 22, n. 8, p. 993-1005, 2013. DENG, Y; CHANG, C; LU, Q. The Inflammatory Response in Psoriasis: a Comprehensive Review. Clin Rev Allergy Immunol, 2016; 50:377-89. FARIA, J. et al. Importância da variação do PASI realizado por diversos observadores. Anais Brasileiros de Dermatologia, v. 85, n. 5, p. 625-9, 2010. GALLUZZO, M. et al. Brodalumab for the treatment of psoriasis,Expert Review of Clinical Immunology, 12:12, 1255-1271, 2016 GORDON, K. et al., Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis, N. Engl. J. Med. V. 375, p. 345–356, 2016. http://dx.doi.org/10.1056/NEJMoa1512711. HONG, C. et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study. Journal of the European Academy of Dermatology and Venereology, v. 31, n. 11, p. 1876-1883, 2017. JINNA, Sphoorthi; STROBER, Bruce. Anti-interleukin-17 treatment of psoriasis.Journal of dermatological treatment, v. 27, n. 4, p. 311-315, 2016. LANGLEY, R. G; et al. Secukinumab in plaque psoriasis—results of two phase 3 trials, N. Engl. J. Med. V. 371, p.326–338, 2014. http://dx.doi.org/10.1056/NEJMoa1314258. LØNNBERG, A. S. et al. Targeting of interleukin-17 in the treatment of psoriasis. Clinical, cosmetic and investigational dermatology, v. 7, p. 251–259, 2014. LOPES, L. et al. Medicamentos biológicos para o tratamento de psoríase em sistema público de saúde. Rev. Saúde Pública, São Paulo, v. 48, n. 4, p. 651-661, 2014. LUNDER, T. et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol, v. 58, n.6, p. 631-641, 2019. MADDUR, M. et al. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol, v. 1, p.181:8-18, 2012. MAIA, C. P. A. et al. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012 - Guias de tratamento Sociedade Brasileira de Dermatologia, 2012. MANSOURI, M. et al.The potential role of Th17 lymphocytes in patients with psoriasis. An Bras Dermatol, v. 93, n. 1, p. 63-6, 2018. MARINONI, B. et al. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights, v. 5, p. 9-19, 2014. MARTI, L. et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann N Y Acad Sci, v.1173, p. 334-42, 2009. MELINDA, G. et al. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett, v. 20, n. 1, p. 1-5, 2015. MROWIETZ, U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol, v. 26, (Suppl 2), p. 12–20, 2012. NAST, A. et al. EuropeanS3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol, v. 29, p. 2277-94, 2015. PATHIRANA, D. et al. "European S3‐Guidelines on the systemic treatment of psoriasis vulgaris: Supported by the EDF/EADV/IPC." Journal of the European Academy of Dermatology and Venereology, v. 23, p. 1-70, 2009. ROMAN, M.; CHIU, M.W. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Design, Development and Therapy; v.11, p. 2065-2075, 2017 SILVA, M. et al. Psoriasis: correlation between clinical severity (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol, v. 88, n. 5, p.760-3, 2013. TORRES, T.; FILIPE, P. Interleukin-17 as a therapeutic target in psoriasis. Acta Med Port, v. 27, n. 2, p. 252-8, 2014. VIDE, J; MAGINA, S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol., Rio de Janeiro, v. 92, n. 5, p. 668-674, 2017. WCISLO-DZIADECKA, D. et al. Are new variants of psoriasis therapy (IL-17 inhibitors) safe? Int J Dermatol. 2019. doi: 10.1111/ijd.14509 YAJIMA et al. Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris. Case Rep Dermatol, v.11, p. 82–85, 2019. | pt_BR |
dc.degree.graduation | Medicina | - |
dc.degree.level | Graduação | - |
Aparece nas coleções: | TCC Medicina |
Arquivos associados a este item:
Arquivo | Tamanho | Formato | |
---|---|---|---|
Artigo Terapia Imunologica Inibidor da IL_17 na Psoriase Vulgar 2020.pdf | 560,25 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.
Ferramentas do administrador